OstiMax (deracoxib) Chewable Tablets for Dogs | On Sale | EntirelyPets Rx
Licensed U.S. Pet Pharmacy | Verified Pharmacy

OstiMax (deracoxib) Chewable Tablets for Dogs

Item#
FREE SHIPPING Over $49! * Pet Food & Other Exclusions
1. Select strength:
2. Select chewable tablets:
QTY:-+

Price too low to show

Add to cart to see low price
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
$0.61Reg $0.37
$17.95Reg $11.01
$52.95Reg $32.95
$0.99Reg $0.59
$30.95Reg $18.91
$91.95Reg $53.27
$1.95Reg $1.17
$57.95Reg $36.15
$172.95Reg $105.21
$2.75Reg $1.65
$81.95Reg $51.92
$244.95Reg $148.61
  • Description
  • Ingredients
  • Directions
  • FAQ
  • Reviews

Description

OstiMax Chewable Tablets are for the control of pain and inflammation due to osteoarthritis or following orthopedic and dental surgery. OstiMax is a highly effective NSAID (non-steroidal, anti-inflammatory drug) that contains the active ingredient, deracoxib, which has been trusted by veterinarians for over 15 years. The tablets are beef flavored to make administration more convenient. For oral use in dogs only.

Key Benefits

  • For dogs of all sizes
  • Inhibits the production of the enzyme that contributes to inflammation
  • Best given with food, but palatable enough to be given without
  • Scored to allow for precise dosing
  • Comes in 4 dosing sizes: 12 mg, 25 mg, 75 mg, and 100 mg

How It Works

Some NSAIDs, such as ibuprofen and naproxen, relieve pain and reduce inflammation by blocking the actions of both COX-1 and COX-2 enzymes. The COX-1 enzyme makes prostaglandins, chemicals necessary for many normal body functions, such as blood clotting, protection of the stomach lining and kidney function. Deracoxib is different from traditional NSAIDs because at recommended doses it blocks the COX-2 enzyme and not the COX-1 enzyme.

Indications

Always provide "Information for Dog Owners" Sheet with prescription. Carefully consider the potential benefits and risk of OstiMax and other treatment options before deciding to use OstiMax. Use the lowest effective dose for the shortest duration consistent with individual response.

Prescription Required

Ingredients

Active Ingredient:

Deracoxib

Directions

Osteoarthritis Pain and Inflammation:

OstiMax Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Dosage and Administration:

Osteoarthritis Pain and Inflammation: 0.45 - 0.91 mg/lb/day (1 to 2 mg/kg/ day) as a single daily dose, as needed.

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience).

Postoperative Orthopedic Pain and Inflammation:

OstiMax Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs.

Dosage and Administration:

Postoperative Orthopedic Pain and Inflammation: 1.4 - 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience).

Postoperative Dental Pain and Inflammation:

OstiMax Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs.

Dosage and Administration:

Postoperative Dental Pain and Inflammation: 0.45 - 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days. The first dose should be given approximately 1 hour prior to dental surgery and subsequent doses should be given daily for up to two additional treatments.

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience).

Since deracoxib chewable tablet bioavailability is greatest when taken with food, postprandial administration is preferable. However, deracoxib chewable tablets have been shown to be effective under both fed and fasted conditions; therefore, they may be administered in the fasted state if necessary. For postoperative orthopedic and dental pain, administer OstiMax tablets prior to the procedure. Tablets are scored and dosage should be calculated in half-tablet increments. In clinical practice it is recommended to adjust the individual patient dose while continuing to monitor the dog's status until a minimum effective dose has been reached.

Contraindications:

Dogs with known hypersensitivity to deracoxib should not receive OstiMax.

Warnings:

Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For use in dogs only. Do not use in cats.

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience).

All dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID is recommended. Owners should be advised to observe for signs of potential drug toxicity (see Adverse Reactions, Animal Safety and Post-Approval Experience) and be given an "Information for Dog Owners" Sheet.

Precautions:

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. Inaccurate dosing may result in adverse drug events (see Adverse Reactions, Animal Safety, and Post-Approval Experience).

Since NSAIDs possess the potential to produce gastrointestinal ulceration and/or perforation, concomitant use of OstiMax tablets with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. As a class, NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. The following collective group of clinical signs has been reported with some serious gastrointestinal events, in decreasing order of reported frequency: anorexia, tachycardia, tachypnea, pyrexia, ascites, pale mucous membranes, dyspnea. In some cases, circulatory shock, collapse and cardiac arrest have also been reported. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/ or hepatic dysfunction. Plasma levels of deracoxib may increase in a greater than dose-proportional fashion above 8 mg/kg/day. Deracoxib tablets have been safely used during field studies in conjunction with other common medications, including heartworm preventatives, anthelmintics, anesthetics, pre-anesthetic medications, and antibiotics. If additional pain medication is needed after a daily dose of OstiMax tablets, a non-NSAID/non-corticosteroid class of analgesic may be necessary. It is not known whether dogs with a history of hypersensitivity to sulfonamide drugs will exhibit hypersensitivity to OstiMax tablets. The safe use of deracoxib tablets in dogs younger than 4 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated.

NSAIDs may inhibit the prostaglandins which maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Appropriate monitoring procedures should be employed during all surgical procedures. The use of parenteral fluids during surgery should be considered to decrease potential renal complications when using NSAIDs perioperatively. Concurrent administration of potentially nephrotoxic drugs should be carefully approached.

The use of concomitantly protein-bound drugs with deracoxib tablets has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of deracoxib tablets has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Animal Safety:

In a 6-month study, dogs were dosed with deracoxib at 0, 2, 4, 6, 8 and 10 mg/kg with food once daily for 6 consecutive months. There were no abnormal feces, and no abnormal findings on clinical observations, food and water consumption, body weights, physical examinations, ophthalmoscopic evaluations, macroscopic pathological examinations, hematology, or buccal bleeding time. Urinalysis results showed hyposthenuria (specific gravity <1.005) and polyuria in one male and one female in the 6 mg/kg group after 6 months of treatment. After 6 months of treatment, the mean BUN values for dogs treated with 6, 8, or 10 mg/kg/day were 30.0, 35.3, and 48.2 mg/dL respectively. No effects were seen on any other clinical chemistry parameters, including other variables associated with renal physiology (serum creatinine, serum electrolytes, and urine sediment evaluation). Dose dependent focal renal tubular degeneration/regeneration was seen in some dogs treated at 6, 8, and 10 mg/kg/day. Focal renal papillary necrosis was seen in 3 dogs dosed at 10 mg/kg/day and in one dog dosed at 8 mg/kg/day. No renal lesions were seen at the label doses of 2 and 4 mg/kg/day. There was no evidence of gastrointestinal, hepatic, or hematopoietic pathology at any of the doses tested.

In a laboratory study, healthy young dogs were dosed with deracoxib tablets once daily, within 30 minutes of feeding, at doses of 0, 4, 6, 8, and 10 mg/kg body weight for 21 consecutive days. No adverse drug events were reported. There were no abnormal findings reported for clinical observations, food and water consumption, body weights, physical examinations, ophthalmic evaluations, organ weights, macroscopic pathologic evaluation, hematology, urinalyses, or buccal mucosal bleeding time. In the clinical chemistry results there was a statistically significant (p<0.0009) dose-dependent trend toward increased levels of blood urea nitrogen (BUN). Mean BUN values remained within historical normal limits at the label dose. No effects on other clinical chemistry values associated with renal function were reported. There was no evidence of renal, gastrointestinal, hepatic or biliary lesions noted during gross necropsy. Renal histopathology revealed trace amounts of tubular degeneration/regeneration in all dose groups including placebo, but no clear dose relationship could be determined. There was no histopathologic evidence of gastrointestinal, hepatic or biliary lesions.

In another study, micronized deracoxib in gelatin capsules was administered once daily to healthy young dogs at doses of 10, 25, 50, and 100 mg/kg body weight for periods up to 14 consecutive days. Food was withheld prior to dosing. Non-linear elimination kinetics occurred at all doses. At doses of 25, 50, and 100 mg/kg, reduced body weight, vomiting, and melena occurred. Necropsy revealed gross gastrointestinal lesions in dogs from all dose groups. The frequency and severity of the lesions increased with escalating doses. At 10 mg/kg, moderate diffuse congestion of gut associated lymphoid tissues (GALT) and erosions/ulcers in the jejunum occurred. At 100 mg/kg, all dogs exhibited gastric ulcers and erosions/ulcerations of the small intestines. There were no hepatic or renal lesions reported at any dose in this study.

In a 13-week study, deracoxib in gelatin capsules was administered to healthy dogs at doses of 0, 2, 4, and 8 mg/kg/day. No test-article related changes were identified in clinical observations, physical exams, or any of the other parameters measured. One dog in the 8 mg/kg dose group died from bacterial septicemia secondary to a renal abscess. The relationship between deracoxib administration and the renal abscess is not clear.

Effectiveness:

Deracoxib tablets were evaluated in masked, placebo-controlled multi-site field studies involving client-owned animals to determine effectiveness.

Information for Dog Owners:

OstiMax, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in some cases result in death (see Warnings, Post-Approval Experience and Adverse Reactions). Owners should be advised to discontinue OstiMax therapy and contact their veterinarian immediately if signs of intolerance are observed.

The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID.

Storage:

OstiMax tablets should be stored at room temperature between 20°C and 25°C (68°F-77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).

Keep this and all medications out of reach of children.

FAQ

OstiMax tablets are a prescription non-steroidal anti-inammatory drug (NSAID) of the coxib class. They are indicated for the control of post-operative pain and inflammation associated with orthopedic (bone) and dental surgery in dogs and for the control of pain and inflammation (soreness) associated with osteoarthritis in dogs. The tablets are flavored to make administration more convenient.

OstiMax tablets allow your dog to recover more comfortably by controlling pain and inflammation that follow orthopedic and dental surgery.

  • The postoperative orthopedic pain dose is a higher dose; administration at this dose should not exceed 7 days total, including the days the patient is administered OstiMax while in the hospital.
  • Control of pain and inflammation may vary from dog to dog.
  • If OstiMax tablets are not given according to your veterinarian's directions, your dog's pain may return.
  • Consult your veterinarian if your dog appears to be uncomfortable.

Osteoarthritis is a painful condition caused by damage to cartilage and other parts of the joint that may result in the following changes or signs in your dog:

  • Limping or lameness
  • Decreased activity or exercise (reluctance to stand, climb stairs, jump or run, or difficulty in performing these activities)
  • Stiffness or decreased movement of jointsWhile OstiMax is not a cure for osteoarthritis, it can control the pain and inflammation of osteoarthritis and improve your dog's mobility. Response may vary from dog to dog but can be quite dramatic.

OstiMax tablets may need to be given on a periodic basis for the animal's lifetime. Use the lowest dose to provide adequate relief. Always consult with your veterinarian before altering the dose.

Your dog should not be given OstiMax tablets if she/he:

  • Has had an allergic reaction to deracoxib, the active ingredient in OstiMax tablets
  • Has had an allergic reaction (such as hives, facial swelling, or red or itchy skin) to aspirin or other NSAIDs
  • Is presently taking aspirin, other NSAIDs, or corticosteroids (unless directed by your veterinarian)
  • Has bloody stool or vomit
  • Has a pre-existing kidney or liver condition
  • Has any condition predisposing to dehydration
  • Is anorexic (loss of appetite)

OstiMax tablets should only be given to dogs. Do not use in cats.

People should not take OstiMax tablets. Keep OstiMax tablets and all medication out of reach of children.

Call your physician immediately if you accidentally take OstiMax tablets.

Tell your veterinarian about:

  • Any side effects your dog has experienced from OstiMax tablets or other NSAIDs
  • Any digestive upset (vomiting or diarrhea) your dog has had
  • Any kidney disease your dog has had
  • Any other medical problems or allergies that your dog has now or has had in the past
  • All medications that you are giving your dog or plan to give your dog, including those you can get without prescription and any dietary supplements
  • If you plan to breed your dog, or if your dog is pregnant or nursing

Talk to your veterinarian about:

  • The orthopedic or dental surgery your dog will undergo
  • What tests might be done before surgery is performed or OstiMax tablets are prescribed
  • The signs of pain or inflammation that may occur after surgery
  • Normal events that can be expected after your dog undergoes surgery
  • The proper amount of exercise after surgery to aid recovery
  • The signs of osteoarthritis you have observed (for example, limping or stiffness)
  • The importance of weight control, physical therapy and exercise in the management of osteoarthritis
  • How often your dog may need to be examined by your veterinarian
  • The risks and benefits of using OstiMax tablets
OstiMax tablets should be given according to your veterinarian's instructions. Your veterinarian will tell you what amount of OstiMax tablets is right for your dog and for how long they should be given.Do not change the way you give OstiMax tablets to your dog without first speaking with your veterinarian. OstiMax tablets should be given by mouth and may be given with or without food, although with food is preferable.

OstiMax tablets may cause some side effects in individual dogs. Serious side effects associated with this drug can occur with or without warning and, in some cases, result in death. The most common side effects associated with OstiMax therapy involve the digestive tract (vomiting, decreased appetite and diarrhea).

Liver and kidney problems have also been reported. It is important to stop the medication and contact your veterinarian immediately if you think your dog may have a medical problem or side effect while on OstiMax tablets. If you have additional questions about possible side effects, talk with your veterinarian or call Ceva Animal Health, LLC at 1-800-999-0297.

Look for the following side effects that may indicate that your dog is having a problem with OstiMax tablets or may have another medical problem:

  • Vomiting
  • Decrease in appetite
  • Change in behavior, such as depression, restlessness, aggression or apprehension
  • Change in bowel movements such as diarrhea or change in stool color (black, tarry or bloody stool)
  • Change in drinking or urination
  • Yellowing of gums, skin or whites of the eyes (jaundice)

OstiMax tablets should not be given with other non-steroidal anti-inammatory drugs (NSAIDs) or corticosteroids (for example, aspirin, carprofen, etodolac, prednisone).

Tell your veterinarian about all medications that you have given your dog in the past, and any medications that you are planning to give with OstiMax tablets. This should include any medications that you can get without a prescription and any dietary supplements. Your veterinarian may want to evaluate the potential for any drug interactions and to assure drug compatibility.

Contact your veterinarian immediately if your dog eats more than the prescribed amount of OstiMax tablets.

This sheet provides a summary of information about OstiMax tablets. If you have any questions or concerns about OstiMax tablets, postoperative orthopedic and dental pain and inflammation, or osteoarthritis, talk to your veterinarian.

As with all prescribed medications, OstiMax tablets should only be given to the dog for which they are prescribed. They should be given to your dog only for the condition for which they were prescribed, at the prescribed dose, as directed by your veterinarian. It is important to periodically discuss your dog's response to OstiMax tablets at regular checkups. Your veterinarian will best determine if your dog is responding as expected and if your dog should continue receiving OstiMax tablets.

Customers Who Bought Also Bought